Tumor-associated antigen specific CD8+T cells in hepatocellular carcinoma – a promising target for immunotherapy
- 2 September 2014
- journal article
- Published by Taylor & Francis in OncoImmunology
- Vol. 3 (9) , e954919
Abstract
Immunotherapy is a promising treatment option for patients with hepatocellular carcinoma (HCC). Indeed, CD8+ T-cell responses against various tumor antigens are present in these patients. However, these antitumoral T cells show a severely impaired effector function. Several immunosuppressive mechanisms contribute to this T-cell failure, including regulatory T cells and inhibitory receptors.Keywords
This publication has 9 references indexed in Scilit:
- Immunodominance and functional alterations of tumor-associated antigen-specific CD8+ T-cell responses in hepatocellular carcinomaHepatology, 2013
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerNew England Journal of Medicine, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Cancer immunotherapy comes of ageNature, 2011
- Hepatocellular CarcinomaNew England Journal of Medicine, 2011
- A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma†Hepatology, 2008
- Comprehensive analysis of the α-fetoprotein-specific CD8+ T cell responses in patients with hepatocellular carcinomaHepatology, 2008
- A Phase I/II Trial Testing Immunization of Hepatocellular Carcinoma Patients with Dendritic Cells Pulsed with Four α-Fetoprotein PeptidesClinical Cancer Research, 2006
- Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trialThe Lancet, 2000